- CA$14.70m
- CA$16.44m
- CA$0.15m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 7.3 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -363.38% | ||
| Return on Equity | n/a | ||
| Operating Margin | -206.71% | ||
Financial Summary
| Year End 31st Dec | Unit | 2019 | 2020 | 2021 | 2022 | 2023 | 2024E | 2025E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | CA$m | 1.69 | 1.34 | 1.61 | 2.67 | 0.15 | n/a | n/a | -20.26% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Kane Biotech Inc. is a Canada-based biotechnology company. The Company is engaged in the research, development and commercialization of technologies and products that prevent and remove microbial biofilms. The Company has a portfolio of biotechnologies, intellectual property (65 patents and patents pending as well as trade secrets and trademarks) and products developed by Kane's own biofilm research and acquired from research institutions. DispersinB, coactiv+, DermaKB, DermaKB Biofilm, and revyve are trademarks of Kane Biotech Inc. Its patented coactiv+ technology is specifically formulated to destabilize biofilm and create an environment for fast wound healing. The Company's other biofilm disruption technology is DispersinB. DispersinB is a naturally occurring enzyme that cleaves the bacterial surface polysaccharide poly-b-1, 6-N-acetylglucosamine (PNAG). DispersinB cleaves PNAG, inhibiting bacterial adhesion and disperses the biofilm.
Directors
- Mark Nawacki NEC (52)
- Marc Edwards PRE
- Raymond Dupuis CFO
- Gordon Guay CSO
- Lori Christofalos VPR
- Nanda Yakandawala VRD
- Wendy Nachtigall DMK
- Allan Mandelzys DRC
- Philip Renaud DRC
- Georges Morin IND
- Sarah Prichard IND
- Last Annual
- December 31st, 2023
- Last Interim
- September 30th, 2024
- Incorporated
- October 9th, 2003
- Public Since
- May 7th, 2003
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
TSX Venture Exchange- Shares in Issue
- 154,771,567
- Address
- 290-100 Innovation Drive, WINNIPEG, R3T 6G2
- Web
- https://kanebiotech.com/
- Phone
- +1 2044531301
- Contact
- Nicole Sendey
- Auditors
- MNP LLP
Upcoming Events for KNE
Kane Biotech Inc Annual Shareholders Meeting
Kane Biotech Inc Annual Shareholders Meeting
Q2 2025 Kane Biotech Inc Earnings Release
Similar to KNE
Aequus Pharmaceuticals
TSX Venture Exchange
Arch Biopartners
TSX Venture Exchange
Biosyent
TSX Venture Exchange
Cytophage Technologies
TSX Venture Exchange
Decibel Cannabis
TSX Venture Exchange
FAQ
What is the Kane Biotech share price?
As of Today at 21:31 UTC, shares in Kane Biotech are trading at CA$0.10. This share price information is delayed by 15 minutes.
How has the Kane Biotech share price performed this year?
Shares in Kane Biotech last closed at CA$0.10 and the price had moved by -26.92% over the past 365 days. In terms of relative price strength the Kane Biotech share price has underperformed the Toronto Stock Exchange 300 Composite Index by -35.03% over the past year.
What are the analyst and broker recommendations for Kane Biotech?
There is no consensus recommendation for this security.
Find out moreWhat is the Kane Biotech dividend yield?
Kane Biotech does not currently pay a dividend.
Does Kane Biotech pay a dividend?
Kane Biotech does not currently pay a dividend.
When does Kane Biotech next pay dividends?
Kane Biotech does not currently pay a dividend.
How do I buy Kane Biotech shares?
To buy shares in Kane Biotech you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of Kane Biotech?
As of the previous close price of CA$0.10, shares in Kane Biotech had a market capitalisation of CA$14.70m.
Where are Kane Biotech shares listed?
Here are the trading details for Kane Biotech:
- Country of listing: Canada
- Exchange: CVE
- Ticker Symbol: KNE
What kind of share is Kane Biotech?
Based on an overall assessment of its quality, value and momentum Kane Biotech is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a Kane Biotech share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the Kane Biotech share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Kane Biotech. Over the past six months, its share price has underperformed the Toronto Stock Exchange 300 Composite Index by -30.04%.
As of the last closing price of CA$0.10, shares in Kane Biotech were trading -19.58% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the Kane Biotech PE Ratio?
The Kane Biotech PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at CA$0.10.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of Kane Biotech?
Kane Biotech's management team is headed by:
- Mark Nawacki - NEC
- Marc Edwards - PRE
- Raymond Dupuis - CFO
- Gordon Guay - CSO
- Lori Christofalos - VPR
- Nanda Yakandawala - VRD
- Wendy Nachtigall - DMK
- Allan Mandelzys - DRC
- Philip Renaud - DRC
- Georges Morin - IND
- Sarah Prichard - IND